Inactive Instrument

Novavax, Inc. Stock price Nasdaq

Equities

US6700021040

Biotechnology & Medical Research

Sales 2024 * 850M Sales 2025 * 929M Capitalization 669M
Net income 2024 * -90M Net income 2025 * - EV / Sales 2024 * 0.19 x
Net cash position 2024 * 510M Net cash position 2025 * 482M EV / Sales 2025 * 0.2 x
P/E ratio 2024 *
-6 x
P/E ratio 2025 *
46.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.33%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 23-01-22
President 64 14-03-09
Director of Finance/CFO 58 21-08-15
Members of the board TitleAgeSince
Director/Board Member 57 22-10-28
Director/Board Member 58 20-10-31
Director/Board Member 58 20-06-15
More insiders
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Novavax, Inc.
  4. Stock Novavax, Inc. - Nasdaq